Mammary gland neoplasia: Insights from transgenic mouse models

BioEssays

Volumn 22, Issue 6, 2000, Pages 554-563

  Siegel, Peter M ^a   Hardy, William R ^a   Muller, William J ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; BREAST CANCER; GENE DISRUPTION; GENE TARGETING; HETEROZYGOSITY; HOMOLOGOUS RECOMBINATION; HUMAN; MAMMARY GLAND; NEOPLASM; ONCOGENE; TRANSGENIC MOUSE;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GENE TARGETING; GENES, TUMOR SUPPRESSOR; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MUTATION; ONCOGENES;

ANIMALIA; EMBRYOPHYTA; MUS MUSCULUS;

EID: 0034123593     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A     Document Type: Review

References (84)

1. Bieche I, Lidereau R. Genetic alterations in breast cancer. Genes Chromosomes 1995;14:227-251.
2. Amundadottir LT, Merlino G, Dickson RB. Transgenic mouse models of breast cancer. Breast Cancer Res Treat 1996;39:119-135.
3. Dankort DL, Muller WJ. Transgenic models of breast cancer metastasis. In R. Dickson and M. Lippman. ed; Mammary tumor cell cycle, differentiation and metastasis. Kluwer Academic Publishers. 1996. p 71-88.
4. Brison O. Gene amplification and tumor progression. Biochim Biophys Acta 1993;1155:25-41.
5. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984;38:627-637.
6. Leder A, Pattengale PK, Kuo A, Stewart TA, Leder P. Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell 1986;45:485-495.
7. Schoenenberger C-A, Andres A-C, Groner B, vand der Valk M, LeMeur M, Gerlinger P. Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumors with constitutive milk protein gene transcription. EMBO J 1988;7:169-175.
8. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-184.
9. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988;54:105-115.
10. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 1989;57:931-936.
11. Luchini F, Sacco MG, Hu N, Villa A, Brown J, Cesano L, Mangiarini L, Rindi G, Kindl S, Sessa F, Vezzoni P, Clerici L. Early and multifocal tumors in breast, salivary. Harderian and epididymal tissues developed in MMTV-Neu transgenic mice. Cancer Letters 1992;64: 203-209.
12. Stocklin E, Botteri F, Groner B. An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice. J Cell Biol 1993;122:199-208.
13. Guy CT, Cardiff RD, Muller WJ. Activated neu induces rapid tumor progression. J Biol Chem 1996;271:7673-7678.
14. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
15. Lemoine NR, Staddon S, Dickson C, Barnes DM, Gullick WJ. Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene 1990;5:237-239.
16. Zoll B, Kynast B, Corell B, Marx D, Fischer G, Schauer A. Alterations of the c-erbB2 gene in human breast cancer. J Cancer Res Clin Oncol 1992;118:468-473.
17. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992;89:10578-10582.
18. Siegel PM, Dankort DL, Hardy WR, Muller WJ. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 1994;14:7068-7077.
19. Siegel PM, Muller WJ. Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. Proc Natl Acad Sci USA 1996;93:8878-8883.
20. Siegel PM, Ryan ED, Cardiff RD, Muller WJ. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in trasgenic mice: implications for human breast cancer. EMBO J 1999;18:2149-2164.
21. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using and EGF receptor/c-erbB-3 chimera. EMBO J 1994;13:2831-2841.
22. Soltoff SP, Carraway III KL, Prigent SA, Gullick WJ, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994;14:3550-3558.
23. Franke TF, Kaplan DR, Cantley LC. P13K: Downstream AKTion blocks apoptosis. Cell 1997;88:435-437.
24. Kwong KY, Hung MC. A novel splice variant of HER2 with increased transformation activity. Mol Carcinog 1998;23:62-68.
25. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994;369:669-671.
26. Webster MA, Cardiff RD, Muller WJ. Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene. Proc Natl Acad Sci USA 1995;92:7849-7853.
27. v-src induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. J Biol Chem 1999;274:7341-7350.
28. Buckley MF, Sweeney KJE, Hamilton JA, Sini RL, Manning DL, Nicholson RI, deFazio A, Watts CKW, Musgrove EA, Sutherland RI. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8: 2127-2133.
29. Keyomarski K, Pardee AB. Redundant cyclin overexpression and gene amplifications breast cancer cells. Proc Natl Acad Sci USA 1993;90: 1112-1116.
30. Keyomarski K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994;54:380-385.
31. Bortner DM, Rosenberg MP. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 1997;17:453-459.
32. Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT. TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 1990;61: 1137-1146.
33. Matsui Y, Halter SA, Holt JT, Hogan BLM, Coffey RJ. Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice. Cell 1990;61:1147-1155.
34. Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL, Lee DC. Overexpression of TGFα in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 1990;61: 1121-1135.
35. Krane IM, Leder P. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 1996;12:1781-1788.
36. Peters G, Brookes S, Smith R, Dickson C. Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell 1983;33:369-377.
37. Dickson C, Smith R, Brookes S, Peters G. Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell 1984;37:529-536.
38. Peters G, Brookes S, Smith R, Placzek M, Dickson C. The mouse homolog of the hst/k-FGF gene is adjacent to int-2 and is activated by proviral insertion in some virally induced mammary tumors. Proc Natl Acad Sci USA 1989;86:5678-5682.
39. MacArthur CA, Shankar DB, Shackleford GM. Fgf-8, activated by proviral insertion, cooperates with the Wnt-1 transgene in murine mammary tumorigenesis. J Virol 1995;69:2501-2507.
40. Kapoun AM, Shackleford GM. Preferential activation of Fgf8 by proviral insertion in mammary tumors of Wnt1 transgenic mice. Oncogene 1997; 14:2985-2989.
41. Muller WJ, Lee FS, Dickson C, Peters G, Pattengale P, Leder P. The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J 1990;9:907-913.
42. Ornitz DM, Moreadith RW, Leder P. Binary system for regulating transgene expression in mice: targeting int-2 expression with yeast GAL4/UAS control elements. Proc Natl Acad Sci USA 1991;88: 698-702.
43. Stamp G, Fantl V, R. P, Jamieson S, Smith R, Peters G, Dickson C. Nonuniform expression of a mouse mammary tumor virus-driven int-2/ Fgf-3 transgene in pregnancy-responsive breast tumors. Cell Growth Diff 1992;3:929-938.
44. Daphna-Iken D, Shankar DB, Lawshe A, Ornitz DM, Shackleford GM, MacArthur CA. MMTV-fgf8 transgenic mice develop mammary gland and salivary gland neoplasia and ovarian stromal hyperplasia. Oncogene 1998;17:2711-2717.
45. Kitsberg DI, Leder P. Keratinocyle growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Oncogene 1996;13:2507-2515.
46. Coleman-Krnacik S, Rosen JM. Differential temporal and spatial gene-expression of fibroblast growth-factor family members during mouse mammary-gland development. Mol Endocrinol 1994;8:218-229.
47. Jackson D, Bresnick J, Rosewell I, Crafton T, Poulsom R, Stamp G, Dickson C. Fibroblast growth factor receptor signalling has a role in lobuloalveolar development of the mammary gland. J. Cell Sci 1997;110: 1261-1268.
48. Niemann C, Brinkmann V, Spitzer E, Hartmann G, Sachs M, Naundorf H, Birchmeier W. Reconstitution of mammary gland development in vitro: requirement of c-met and c-erbB2 signaling for branching and alveolar morphogenesis. J Cell Biol 1998;143:533-545.
49. Yang Y, Spitzer E, Meyer D, Sachs M, Niemann C, Hartmann G, Weidner KM, Birchmeier C, Birchmeier W. Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J Cell Biol 1995;131:215-226.
50. Yamashita J-I, Ogawa M, Yamashita S-I, Nomura K, Kuramoto M, Saishoji T, Shin S. Immunoreactice hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994;54:1630-1633.
51. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Amer J Path 1996;148:225-232.
52. Jin L, Fuchs A, Schitts SJ, Yao Y, Joseph A, Lamszus K, Park M, Goldberg ID, Rosen EM. Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer 1997;79:749-760.
53. Liang TJ, Reid AE, Xavier R, Cardiff RD, Wang TC. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J Clin Invest 1996;97:2872-2877.
54. Jeffers M, Fiscella M, Webb CP, Anver M, Koochekpour S, Vande Woude GF. The mutationally activated Met receptor mediates motility and metastasis. Proc Natl Acad Sci USA 1998;95:14417-14422.
55. Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte grown factor/scatter factor. Proc Natl Acad Sci USA 1997;94:701-706.
56. Radany EH, Hong K, Kesharvarzi S, Lander ES, Bishop JM. Mouse mammary tumor virus/v-Ha-ras transgene-induced mammary tumors exhibit strain-specific allelic loss on mouse chromosome 4. Proc Natl Acad Sci. USA 1997;94:8664-8669.
57. Ritland SR, Rowse GJ, Chang Y, Gendler SJ. Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. Cancer Res 1997;57: 3520-3525.
58. Weaver ZA, McCormack SJ, Liyanage M, du Manoyr S, Coleman A, Schrock E, Dickson RB, Ried T. A recurring pattern of chromosomal aberrations in mammary gland tumors of MMTV-cmyc transgenic mice. Genes Chromosomes Cancer 1999;25:251-260.
59. Cool M, Jolicoeur P. Elevated frequency of loss of heterozygosity in mammary tumors arising in mouse mammary tumor virus/neu lransgenic mice. Cancer Res 1999;59:2438-2444.
60. Bertwistle D, Ashworth A. Functions of the BRCA1 and BRCA2 genes. Curr Opin Genes Dev 1998;8:14-20.
61. Xu X, Wagner K-U, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Borris A, Deng C-X. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat Gen 1999;22:37-43.
62. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999;4:511-518.
63. Elledge RM, Allred DC. The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 1994;32:39-47.
64. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr. CA, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-221.
65. Li B, Murphy KL, Laucirica F, Medina D, Rosen JM. A transgenic mouse model for mammary carcinogenesis. Oncogene 1998;16:997-1007.
66. Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumongenesis in the mammary gland and lung in response to the carcinogen 7,12-Dimethylbenz-[a]-anthracene. Cancer Res 1997;57:5564-5570.
67. Gorska AE, Joseph H, Derynck R, Moses HL, Serra R. Dominant-negative interference of the transforming growth lactor β type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Diff 1998;9:229-238.
68. Sinn E, Muller WJ, Pattengale P, Tepler I, Wallace R, Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987;49:465-475.
69. Amundadottir LT, Johnson MD, Merlino G, Smith GH, Dickson RB. Synergistic interaction of transforming growth factor α and c-myc in mouse mammary and salivary gland tumorigenesis. Cell Growth Diff 1995;6:737-748.
70. Amundadottir LT, Nass SJ, Berchem GJ, Johnson MD, Dickson RB. Cooperation of TGFα and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. Oncogene 1996;13:757-765.
71. Muller WJ, Arteaga CL, Muthuswamy SK, Siegel PM, Webster MA, Cardiff RD, Meise KS, Li F, Halter SA, Coffey RJ. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor α in the mammary epithelium of transgenic mice. Mol Cell Biol 1996;16: 5726-5736.
72. Li B, Rosen JM, McMenamin-Balano J, Muller WJ, Perkins AS. neu/ ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol 1997;17:3155-3163.
73. Pierce DF, Gorska AE, Chytil A, Meise KS, Page DL, Coffey Jr. RJ, Moses HL. Mammary tumor suppression by transforming growth factor β1 trangene expression. Proc Natl Acad Sci USA 1995;92:4254-4258.
74. Arteaga CL, Dugger TC, Hurd SD. The multifunctional role of transforming growth factor (TGF)-βs on mammary epithelial cell biology. Breast Cancer Res Treat 1996;38:49-56.
75. Taipale J, Saharinen J, Keski-Oja J. Extracellular matrix-associated transforming growth factor β: role in cancer cell growth and invasion. Adv Cancer Res 1998;87-134.
76. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Weiser R, Massague J, Mundy GR, Guise TA. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206.
77. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev 1994;8:23-32.
78. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988;55:619-625.
79. Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi Y-P, Pinkel D, Gray J, Bradley A, Medina D, Varmus HE. Deficiency of p53 accelerates mammary tumongenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 1995;9:882-895.
80. Elson A, Deng C, Camos-Torres J, Donehower LA, Leder P. The MMTV/ c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene 1995;11:181-190.
81. Hundley JE, Koester SK, Troyer DA, Hilsenbeck SG, Subler MA, Windle JJ. Increased tumor proliferation and genomic instability without decreased apoptosis in MMTV-ras mice deficient in p53. Mol Cell Biol 1997;17:723-731.
82. Cressman VL, Backlund DC, Hicks EM, Gowen LC, Godfrey V, Koller VH. Mammary tumor formation in p53-and BRCA1-deficient mice. Cell Growth Differ 1999;10:1-10.
83. Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS. A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res 1999;59:1869-1876.
84. Fisher GH, Orsulic S, Holland E, Hively WP, Li Y, Lewis BC, Williams BO, Varmus HE. Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene 1999;18:5253-5260.